Rhumbline Advisers raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 13.9% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,660 shares of the company’s stock after acquiring an additional 6,070 shares during the quarter. Rhumbline Advisers owned approximately 0.13% of Tarsus Pharmaceuticals worth $1,350,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Tarsus Pharmaceuticals by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 122,634 shares of the company’s stock worth $3,333,000 after buying an additional 26,225 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $28,904,000. Janus Henderson Group PLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter worth $313,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter worth $12,640,000. Institutional investors own 90.01% of the company’s stock.
Tarsus Pharmaceuticals Trading Down 0.3 %
Shares of NASDAQ TARS opened at $34.51 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.23 and a beta of 1.06. Tarsus Pharmaceuticals, Inc. has a 1-year low of $12.57 and a 1-year high of $42.50. The business has a fifty day moving average price of $27.44 and a 200 day moving average price of $31.05.
Analysts Set New Price Targets
Several brokerages have weighed in on TARS. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reiterated an “outperform” rating and issued a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $51.60.
View Our Latest Stock Analysis on TARS
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
- Five stocks we like better than Tarsus Pharmaceuticals
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Plot Fibonacci Price Inflection Levels
- MarketBeat Week in Review – 9/16 – 9/20
- How Can Investors Benefit From After-Hours Trading
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report).
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.